hERG liability classification models using machine learning techniques

Abstract Known for its critical role in cardiac action potential repolarization, the voltage-dependent hERG K+ channel is one of the most prominent anti-targets determining cardio-toxicity of drugs. Inhibition of hERG leads to QT interval prolongation, Torsades de Pointes and sudden death. As testing of hERG liability is mandatory and the standard experimental screening is complex, exorbitant, and tedious, there is a considerable interest for developing predictive computational (in silico) tools to identify and filter out potential hERG blockers early in drug discovery process. Here, we aimed to build robust descriptor-based QSAR and predictive models for hERG liability with different potency threshold cutoffs (1 µM, 10 µM and 30 µM) by using a large curated dataset of 8705 compounds, 2D descriptors and by applying machine learning techniques. The pipeline yielded accuracies of 0.87 (N = 222, literature mined test set), 0.95 (N = 277, Pubchem BioAssay) and 0.98 (N = 86, in-house data) when tested on 3 different external validation sets. Incorporation of similarity information with combined models enhanced the prediction performance. The consensus model prediction performance on overall external dataset (N = 499, literature mined and Pubchem BioAssay datasets only) showed accuracy = 0.92, CCR = 0.876, MCC = 0.786, sensitivity = 0.963 and specificity = 0.786 which is better than several existing models. The performance of our consensus model shows an improvement of 16% to 52% in discriminating blockers from non-blockers accurately compared to the other existing models. Owing to improved prediction performance, our consensus model can serve as a useful tool for screening the molecules, reducing time, cost and animal testing.

[1]  Jie Shen,et al.  admetSAR: A Comprehensive Source and Free Tool for Assessment of Chemical ADMET Properties , 2012, J. Chem. Inf. Model..

[2]  Jun Chen,et al.  A structural basis for drug-induced long QT syndrome. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[3]  G. Keserü Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods. , 2003, Bioorganic & medicinal chemistry letters.

[4]  Woody Sherman,et al.  Analysis and comparison of 2D fingerprints: insights into database screening performance using eight fingerprint methods , 2010, J. Cheminformatics.

[5]  Scott Boyer,et al.  Development, interpretation and temporal evaluation of a global QSAR of hERG electrophysiology screening data , 2007, J. Comput. Aided Mol. Des..

[6]  T. Nishikawa,et al.  A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors. , 2005, Bioorganic & medicinal chemistry letters.

[7]  Yuye He,et al.  PaDEL‐DDPredictor: Open‐source software for PD‐PK‐T prediction , 2013, J. Comput. Chem..

[8]  Hugo A Katus,et al.  The antipsychotic drug chlorpromazine inhibits HERG potassium channels , 2003, British journal of pharmacology.

[9]  Jules C Hancox,et al.  The hERG potassium channel and hERG screening for drug-induced torsades de pointes. , 2008, Pharmacology & therapeutics.

[10]  D. Rampe,et al.  The antipsychotic agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERG. , 1998, The Journal of pharmacology and experimental therapeutics.

[11]  S. Gottlieb Antihistamine drug withdrawn by manufacturer , 1999, BMJ.

[12]  Antranig Basman,et al.  HERG binding specificity and binding site structure: evidence from a fragment-based evolutionary computing SAR study. , 2004, Progress in biophysics and molecular biology.

[13]  J. Li,et al.  A two-state homology model of the hERG K+ channel: application to ligand binding. , 2005, Bioorganic & medicinal chemistry letters.

[14]  Spencer J. Dech,et al.  Improved throughput of PatchXpress hERG assay using intracellular potassium fluoride. , 2008, Assay and drug development technologies.

[15]  Roy J. Vaz,et al.  Characterization of HERG potassium channel inhibition using CoMSiA 3D QSAR and homology modeling approaches. , 2003, Bioorganic & medicinal chemistry letters.

[16]  Douglas E. V. Pires,et al.  pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures , 2015, Journal of medicinal chemistry.

[17]  P. Fernandes,et al.  Predictive QSAR models development and validation for human ether-a-go-go related gene (hERG) blockers using newer tools , 2014, Journal of enzyme inhibition and medicinal chemistry.

[18]  Jules C Hancox,et al.  Troubleshooting problems with in vitro screening of drugs for QT interval prolongation using HERG K+ channels expressed in mammalian cell lines and Xenopus oocytes. , 2002, Journal of pharmacological and toxicological methods.

[19]  S. Sathiya Keerthi,et al.  Improvements to Platt's SMO Algorithm for SVM Classifier Design , 2001, Neural Computation.

[20]  John P. Overington,et al.  ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..

[21]  John B. O. Mitchell,et al.  Development and Comparison of hERG Blocker Classifiers: Assessment on Different Datasets Yields Markedly Different Results , 2011, Molecular informatics.

[22]  W. Crumb,et al.  Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel. , 2002, The Journal of pharmacology and experimental therapeutics.

[23]  Robert Preissner,et al.  The Catch-22 of Predicting hERG Blockade Using Publicly Accessible Bioactivity Data , 2018, J. Chem. Inf. Model..

[24]  Igor V. Tetko,et al.  Combinatorial QSAR Modeling of Chemical Toxicants Tested against Tetrahymena pyriformis , 2008, J. Chem. Inf. Model..

[25]  T. Danker,et al.  Early identification of hERG liability in drug discovery programs by automated patch clamp , 2014, Front. Pharmacol..

[26]  A. Tropsha,et al.  Beware of q2! , 2002, Journal of molecular graphics & modelling.

[27]  D. Wortham,et al.  Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. , 1993, JAMA.

[28]  Alexander Tropsha,et al.  Tuning HERG out: antitarget QSAR models for drug development. , 2014, Current topics in medicinal chemistry.

[29]  Rita R. Patel,et al.  A High-Throughput HERG Potassium Channel Function Assay: An Old Assay with a New Look , 2002, Drug development and industrial pharmacy.

[30]  Anthony E. Klon,et al.  Machine learning algorithms for the prediction of hERG and CYP450 binding in drug development , 2010, Expert opinion on drug metabolism & toxicology.

[31]  CHUN WEI YAP,et al.  PaDEL‐descriptor: An open source software to calculate molecular descriptors and fingerprints , 2011, J. Comput. Chem..

[32]  Stefan Kramer,et al.  Filtered circular fingerprints improve either prediction or runtime performance while retaining interpretability , 2016, Journal of Cheminformatics.

[33]  S. Polak,et al.  hERG in vitro interchange factors—development and verification , 2009, Toxicology mechanisms and methods.

[34]  Yanli Wang,et al.  PubChem BioAssay: 2017 update , 2016, Nucleic Acids Res..

[35]  Charles H Large,et al.  Automated patch clamping using the QPatch. , 2009, Methods in molecular biology.

[36]  Chun Wei Yap,et al.  Determination of torsade-causing potential of drug candidates using one-class classification and ensemble modelling approaches. , 2012, Current drug safety.

[37]  Alexander Tropsha,et al.  Best Practices for QSAR Model Development, Validation, and Exploitation , 2010, Molecular informatics.

[38]  Tudor I. Oprea,et al.  hERG classification model based on a combination of support vector machine method and GRIND descriptors. , 2008, Molecular pharmaceutics.

[39]  Alan Finkel,et al.  Population Patch Clamp Improves Data Consistency and Success Rates in the Measurement of Ionic Currents , 2006, Journal of biomolecular screening.

[40]  Dimitris K Agrafiotis,et al.  A QSAR Model of hERG Binding Using a Large, Diverse, and Internally Consistent Training Set , 2006, Chemical biology & drug design.

[41]  John C. Platt,et al.  Fast training of support vector machines using sequential minimal optimization, advances in kernel methods , 1999 .

[42]  Borje Darpo,et al.  Clinical Evaluation of QT/QTc Prolongation and Proarrhythmic Potential for Nonantiarrhythmic Drugs: The International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use E14 Guideline , 2006, Journal of clinical pharmacology.

[43]  Brian B. Goldman,et al.  A model for identifying HERG K+ channel blockers. , 2004, Bioorganic & medicinal chemistry.

[44]  Victor Guallar,et al.  Importance of accurate charges in molecular docking: Quantum mechanical/molecular mechanical (QM/MM) approach , 2005, J. Comput. Chem..

[45]  Aarti Desai,et al.  Integrated Computational Solution for Predicting Skin Sensitization Potential of Molecules , 2016, PloS one.

[46]  I. Kola,et al.  Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.

[47]  Youyong Li,et al.  ADMET evaluation in drug discovery. 12. Development of binary classification models for prediction of hERG potassium channel blockage. , 2012, Molecular pharmaceutics.

[48]  Gang Fu,et al.  PubChem Substance and Compound databases , 2015, Nucleic Acids Res..

[49]  Robert Tibshirani,et al.  Classification by Pairwise Coupling , 1997, NIPS.

[50]  Matthew Clark,et al.  Development and Evaluation of an in Silico Model for hERG Binding , 2006, J. Chem. Inf. Model..

[51]  Roberto Todeschini,et al.  Handbook of Molecular Descriptors , 2002 .

[52]  Woody Sherman,et al.  Large-Scale Systematic Analysis of 2D Fingerprint Methods and Parameters to Improve Virtual Screening Enrichments , 2010, J. Chem. Inf. Model..

[53]  J C Madden,et al.  Integrating (Q)SAR models, expert systems and read-across approaches for the prediction of developmental toxicity. , 2010, Reproductive toxicology.

[54]  Leo Breiman,et al.  Random Forests , 2001, Machine Learning.

[55]  Judith C. Madden,et al.  Formation of Structural Categories to Allow for Read‐Across for Teratogenicity , 2009 .

[56]  Alexander Tropsha,et al.  Pred‐hERG: A Novel web‐Accessible Computational Tool for Predicting Cardiac Toxicity , 2015, Molecular informatics.

[57]  Qiuming Gong,et al.  Blockage of the HERG human cardiac K+ channel by the gastrointestinal prokinetic agent cisapride. , 1997, American journal of physiology. Heart and circulatory physiology.

[58]  A. Cavalli,et al.  Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers. , 2002, Journal of medicinal chemistry.

[59]  Christopher M. Bishop,et al.  Neural networks for pattern recognition , 1995 .

[60]  Simon Haykin,et al.  Neural Networks: A Comprehensive Foundation , 1998 .

[61]  Gerhard F. Ecker,et al.  Classification Models for hERG Inhibitors by Counter‐Propagation Neural Networks , 2008, Chemical biology & drug design.

[62]  R. Lazzara,et al.  Spontaneous Adverse Event Reports of Serious Ventricular Arrhythmias, QT Prolongation, Syncope, and Sudden Death in Patients Treated with Cisapride , 2002, Journal of cardiovascular pharmacology and therapeutics.

[63]  Clemens Möller,et al.  Automated Electrophysiology Makes the Pace for Cardiac Ion Channel Safety Screening , 2011, Front. Pharmacol..

[64]  Noel Southall,et al.  Prediction of hERG Liability – Using SVM Classification, Bootstrapping and Jackknifing , 2017, Molecular informatics.

[65]  Prabha Garg,et al.  Role of breast cancer resistance protein (BCRP) as active efflux transporter on blood-brain barrier (BBB) permeability , 2014, Molecular Diversity.

[66]  Karl-Heinz Boven,et al.  Micro-Electrode Arrays in Cardiac Safety Pharmacology , 2004, Drug safety.

[67]  Alexander Tropsha,et al.  Trust, But Verify: On the Importance of Chemical Structure Curation in Cheminformatics and QSAR Modeling Research , 2010, J. Chem. Inf. Model..

[68]  Gary R. Mirams,et al.  Variability in high-throughput ion-channel screening data and consequences for cardiac safety assessment , 2013, Journal of pharmacological and toxicological methods.

[69]  R. Friesner,et al.  New insights about HERG blockade obtained from protein modeling, potential energy mapping, and docking studies. , 2006, Bioorganic & medicinal chemistry.

[70]  Jerzy Leszczynski,et al.  Consensus QSAR Modeling of Phosphor‐Containing Chiral AChE Inhibitors , 2009 .

[71]  Andreas Ebneth,et al.  Evaluation of a High-Throughput Fluorescence Assay Method for hERG Potassium Channel Inhibition , 2005, Journal of biomolecular screening.

[72]  Simone Brogi,et al.  Computational Tool for Fast in silico Evaluation of hERG K+ Channel Affinity , 2017, Front. Chem..

[73]  C. January,et al.  [3H]dofetilide binding to HERG transfected membranes: a potential high throughput preclinical screen. , 2001, European journal of pharmacology.